Stockwatch

Date	Sym	Type	Headline
2024-04-30 08:30	UU:NRXP	News Release200	NRx Pharmaceuticals (Nasdaq:NRXP) Announces Promising Findings in Phase 2b/3 Clinical Trial of NRX-101 vs. Lurasidone for Treatment of Suicidal Bipolar Depression
2024-04-18 08:32	UU:NRXP	News Release200	NRx Pharmaceuticals (NASDAQ:NRXP) Receives Notice from Nasdaq that the Company has Demonstrated Compliance with the Bid Price Requirement
2024-04-18 08:30	UU:NRXP	News Release200	NRx Pharmaceuticals, Inc. Announces Pricing of $2.0 Million Underwritten Public Offering of Common Stock
2024-04-17 16:45	UU:NRXP	News Release200	NRx Pharmaceuticals, Inc. Announces Proposed Underwritten Public Offering of Common Stock
2024-04-17 08:30	UU:NRXP	News Release200	NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces New Data on NRX-101 Demonstrating No Damage to Intestinal and Vaginal Flora in Validated Rodent Models Compared to Standard Antibiotics: Potential Implications for Avoidance of C. Difficile infections
2024-04-15 08:30	UU:NRXP	News Release200	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Development of New, Proprietary Formulation of HTX-100 (IV Ketamine)
2024-04-08 08:30	UU:NRXP	News Release200	NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
2024-04-01 08:28	UU:NRXP	News Release200	NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2024-03-28 08:03	UU:NRXP	News Release200	NRx Pharmaceuticals (NASDAQ:NRXP) Reports Preliminary Fourth Quarter and Full Year 2023 Financial Results and Provides Year End Highlights
2024-03-28 08:00	UU:NRXP	News Release200	NRx Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
2024-03-26 16:03	UU:NRXP	News Release200	UPDATE: NRx Pharmaceuticals (NASDAQ: NRXP) to Report Fourth Quarter and Full Year 2023 Financial Results on March 28, 2024